Background Citalopram and escitalopram, selective serotonin reuptake inhibitors, are primarily metabolized by cytochrome P450 (CYP) 2C19, which is a highly polymorphic enzyme known to cause inter-individual differences in pharmacokinetics. However, the impact of CYP2C19 polymorphisms on citalopram or escitalopram exposure has yet to be fully clarified, especially with regard to the quantitative impact of the CYP2C19*17 allele. Objective The objective of this study was to quantify the effect of functional CYP2C19 allele variants on citalopram/escitalopram exposure. Methods We performed a systematic review and metaanalysis with a structured search algorithm and eligibility criteria for including related studies, calculating the change of citalopram or escitalopram exposure associated with CYP2C19*2, *3, and *17 as compared with CYP2C19*1 using fixed-effect and random-effects models. Assessment of publication bias was performed by means of funnel plots and sensitivity analysis using meta-regressions. The predefined review protocol was registered at the PROSPERO international prospective register of systematic reviews, registration number CRD42013004106. Results Sixteen studies from 14 publications met the inclusion criteria. Eligible studies included 847 patients from psychiatric patient trials and 140 healthy subjects from pharmacokinetic studies. Compared to subjects with the EM/EM (CYP2C19*1/*1) genotype, the exposure to (es)citalopram increased by 95 % (95 % CI 40-149, p \ 0.0001) in the poor metabolizer (PM)/PM (CYP2C19*2 or *3/*2 or *3), 30 % (95 % CI 4-55, p \ 0.05) in the extensive metabolizer (EM)/PM (CYP2C19*1/*2 or *3), and 25 % (95 % CI 1-49, p \ 0.05) in the ultrarapid metabolizer (UM)/PM (CYP2C19*17/*2 or *3) groups. In contrast, the exposure to (es)citalopram decreased by 36 % (95 % CI 27-46, p \ 0.0001) in the UM/UM (CYP2C19*17/*17) and by 14 % (95 % CI 1-27, p \ 0.05) in the UM/EM (CYP2C19*17/*1). Interpretation This is the first meta-analysis based on a systematic review of accumulated information that addresses the relationship between CYP2C19 genotypes and the exposure to citalopram or escitalopram. All functional CYP2C19 genotype groups demonstrated significant effects on (es)citalopram exposure. The findings based on our pooled analysis are likely to help in understanding the interindividual variability in the exposure to citalopram and escitalopram in psychiatric patients and to facilitate dose selection, particularly for the homozygous carriers of CYP2C19*2 or *3 (loss of function) and CYP2C19*17 (gain of function) alleles. The results could improve individualization of citalopram or escitalopram therapy and could also be used for physiologically based pharmacokinetic modeling as well as pharmacokinetic/pharmacodynamic modeling.
Introduction
Citalopram and escitalopram are selective serotonin reuptake inhibitors (SSRIs) widely used for the treatment of depression and anxiety disorders [1] . Escitalopram is the S-enantiomer of racemic citalopram and binds with high affinity to the human serotonin transporter [2] . Pharmacokinetic parameters for escitalopram are similar in human subjects regardless of citalopram 40 mg or escitalopram 20 mg being administered [3, 4] . Both citalopram and escitalopram are primarily metabolized by cytochrome P450 (CYP) 2C19 and to a lesser extent via CYP3A4 and CYP2D6 [5] .
CYP2C19 is a highly polymorphic enzyme known to cause inter-individual differences in pharmcokinetics and pharmacodynamics, exemplified by differences in the disposition of omeprazole and its effect on plasma gastrin levels [6] . Among the many characterized polymorphic variants of CYP2C19, CYP2C19*2 and CYP2C19*3 account for the majority of the defective (or loss of function) alleles associated with the poor metabolizer (PM) phenotype. Several studies have investigated the effect of CYP2C19*2 and CYP2C19*3 on citalopram and escitalopram exposure and its clinical implications [7] . Another CYP2C19 variant allele, CYP2C19*17, was identified in 2006 [8] . As this variant is associated with increased levels of gene expression and enzyme activity, it is considered a gain of function allele. A few studies have been conducted to examine the impact of CYP2C19*17 on steady-state escitalopram or citalopram concentrations and clinical outcomes [9] [10] [11] [12] [13] .
The pharmacogenetic studies of citalopram and escitalopram have yielded somewhat contradictory results, especially with regard to the quantitative impact of the CYP2C19*17 allele [9, 10] . More importantly, most studies were not powered to provide useful quantitative estimates of the genotype effect. From a pharmacodynamic standpoint, fewer than 50 % of patients treated with SSRIs, including citalopram or escitalopram, experience a complete remission of their symptoms [14] . Insufficient drug exposure is deemed to be one of a number of factors contributing to the low response rate.
The aim of this study was to quantify the effect of CYP2C19 polymorphisms on (es)citalopram exposure by means of a systematic review and a meta-analysis on the association between CYP2C19 loss of function or gain of function alleles and drug exposure outcomes.
Methods

Search Strategy
Following the MOOSE (Meta-analysis Of Observational Studies in Epidemiology) proposal [15] ' ' without restrictions on timespan, science categories, and document types. Scanning of the reference list of review articles was conducted manually and relevant studies, which were absent from the electronic searches, were included and identified from other sources. In case of non-clarity or missing data, authors were contacted for additional information.
Eligibility Criteria
All publications reporting single-or multiple-dose citalopram or escitalopram serum/plasma concentrations or area under the concentration-time curve (AUC) together with data on CYP2C19 polymorphisms were eligible for inclusion. To simplify the process and graphic reporting, the CYP2C19 genotype categories were assigned as follows: CYP2C19*1/*1 = extensive metabolizer (EM)/EM, CYP2C19*17/*17 = ultrarapid metabolizer (UM)/UM, CYP2C19*17/*1 = UM/EM, CYP2C19*17/*2 or *3 = UM/ PM, CYP2C19*1/*2 or *3 = EM/PM, and CYP2C19*2 or *3/*2 or *3 = PM/PM. Studies assessing the CYP2C19 polymorphism by phenotyping using probe drugs were also included in a separate analysis. CYP2C19 phenotype categories were expressed as EMpheno for the EMs and PMpheno for the PMs. Dose titration of citalopram or escitalopram was allowed. There were no restrictions on study design, subject characteristics (including ethnicity), treatment duration, concomitant drugs, or year of publication. However, the studies must meet the following criteria to be included: (1) all subjects received at least one single dose of citalopram or escitalopram orally; (2) either genotyping or phenotyping of CYP2C19 was performed in all subjects; (3) citalopram or escitalopram exposure level [mean and standard deviation (SD)] was presented separately for the EM/EM genotype group and at least one of the following groups: UM/UM, UM/EM, UM/ PM, EM/PM, PM/PM; and (4) if polymorphism was only assessed by phenotyping, citalopram or escitalopram exposure was reported separately for the EMpheno and PMpheno groups.
Data Extraction
The initial data extraction including authors, journal and year of publication, population characteristics, doses and treatment duration, genotypes, phenotypes, and pharmacokinetic outcome measures was performed and summarized by MC (Ming Chang). The evaluation for eligibility was conducted by JDL (Jonatan D. Lindh) and MC, consulting with MLD (Marja-Liisa Dahl). All reports deemed eligible for inclusion were retrieved in full-text and the relevant data were re-extracted independently by GT (Gunnel Tybring). Any discrepancies during dataset preparation were resolved by consensus.
The predefined review protocol was registered at the PROSPERO international prospective register of systematic reviews, ID CRD42013004106 (http://www.crd.york. ac.uk/PROSPERO/display_record.asp?ID=CRD420130041 06#.U2hKZIFdXRV). The protocol for this study is available as in the Electronic Supplementary Material as Supporting Information S1. A full list of extracted data items is also presented in Supporting Information S2.
Statistical Analyses
In studies where all subjects received identical (es)citalopram doses, the AUC was used as primary outcome measure. When doses differed between subjects, dose-adjusted steady-state trough concentrations (C ss ) or AUCs were calculated and taken as substitutes. To allow comparison between CYP2C19 polymorphism groups using different outcome measures (C ss , AUC, and substitutes), and to account for population differences unrelated to CYP2C19 genotype, outcome estimates were normalized within each study prior to the meta-analyses. The normalization procedure was performed as described previously [16] by dividing the mean drug exposure (C ss , AUC, and substitutes) and associated SD in each genotype/phenotype group by the mean exposure in the reference group (EM/EM group or EMpheno group as appropriate). This procedure removes differences unrelated to CYP2C19 polymorphisms, including the use of different outcome measures. It also means that the calculated between-group mean differences (MDs) represent relative rather than absolute differences in exposure. In case of SD data missing from the individual studies, it was re-calculated from available measures of variability or retrieved from authors.
Pooled-effect estimates were calculated by means of fixed-effect and random-effects meta-analyses where MDs in normalized (es)citalopram exposure were compared between individual genotype/phenotype groups and the reference group. The fixed-effect model is based on the assumption that all differences in outcome between studies are due to random sampling variation whereas the randomeffects model assumes that part of the differences in outcome is due to actual differences with regard to study populations, study designs, and other key variables. In these meta-analyses, studies were weighted according to inverse variance, which gives higher weight to studies with better precision, since their effect estimates are likely to lie closer to the true effect.
Heterogeneity among studies was assessed using the Cochran's Q test at a significance level of 0.10 (p value). In addition, the percentage of total variability across studies attributable to heterogeneity rather than chance was quantified by I 2 . When substantial heterogeneity was demonstrated (defined as a Cochran Q test p value \0.1 or an I 2 value [25 %, which is generally considered to represent low heterogeneity), only the results derived from the random-effect model were deemed to be reliable, otherwise the fixed-effect model was used.
Study-level, random-effects, weighted univariable linear regression was used to investigate potential sources of heterogeneity and the impact of study characteristics on the association between polymorphism and drug exposure. The following potential confounders (or independent variables) were assessed in the sensitivity analyses: citalopram versus escitalopram as study drug, use of AUC versus C ss as outcome measure, healthy subjects versus patients, gender (percentage males), Caucasian ethnicity ([90 % of participants), Asian ethnicity ([90 % of participants), and inclusion of CYP2C19*17 among the CYP2C19 polymorphisms analyzed. Binary coding was used for all variables except for gender distribution. In addition, studies using escitalopram and studies using racemic citalopram were analyzed separately in a post hoc subgroup analysis.
To assess potential bias from small study effects, funnel plots displaying MD of the individual studies on the horizontal axis and standard errors on the vertical axis were constructed. Funnel plot asymmetries indicative of publication bias were detected by visual inspection and Egger's test.
All statistical analyses were performed using R 2.11.1 (R Development Core Team, Vienna, Austria, [17] ). In all analyses except the Cochran Q test, p values \0.05 were considered statistically significant.
Results
Study Selection
A total of 5,365 publication records were identified in the initial literature search. As described in Fig. 1, 4 ,978 records were excluded due to lack of either pharmacokinetic or CYP2C19 data or both. After removal of duplicates, 85 full-text articles were retrieved and examined for eligibility. Publications where genotyping or phenotyping of CYP2C19 had only been reported in some of the participants or the exposure outcome was not presented per genotype/phenotype group were excluded. For five records, authors were contacted with requests for additional unpublished data but only one responded. The study did not eventually meet the inclusion criteria and was thus not included. Overall, 14 publications met the inclusion criteria. Among them, one [18] reported both citalopram and escitalopram data separately and another [19] classified the subjects' CYP2C19 status using both genotype and phenotype methods. Each of these two reports was split into two separate datasets, treated as separate studies in the meta-analyses. Therefore, a total of 16 studies from 14 publications were included in the meta-analyses [9] [10] [11] [12] [13] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Characteristics of Included Studies
Characteristics of the 16 studies from 14 publications are presented in Table 1 . All records were published between 1993 and 2014. Three studies were performed in Asia and 13 in Europe (11 in the Nordic countries). Eight studies assessed pharmacokinetics in healthy subjects, and the others were performed in psychiatric patient populations. A total of 987 subjects were included of whom 39.6 % were men (range 12-100 % in the 16 studies included). The age of the participants ranged from 15 to 84 years. The evaluable data for the final meta-analyses included 395 
Synthesis of Results
The results of the six meta-analyses are presented in Fig. 2 . In addition, the overall influences of individual CYP2C19 genotypes/phenotypes on (es)citalopram exposure are presented side-by-side in Fig. 3 , to enable comparison. A significant heterogeneity among included studies was found in two comparisons (EM/PM vs. EM/EM and PM/PM vs. EM/ EM). Hence, the random-effects estimates were presented in these comparisons rather than the fixed-effect estimates. All variant CYP2C19 genotypes demonstrated significant effects on (es)citalopram exposure as compared to EM/EM, the effect ranging from a 36 % reduction in UM/UM individuals (Fig. 2a) to a 95 % increase in those with the PM/ PM genotype (Fig. 2e) . The PMs identified by phenotyping (PMpheno) (Fig. 2f) produced results similar to those characterized by genotyping (PM/PM).
Risk of Bias Across Studies
Indications of publication bias were assessed based on the funnel plots for the six comparisons (Electronic Supplementary Material Fig. 1 
Additional Analyses
Sensitivity analyses by means of meta-regressions were performed to assess the impact of potential confounders on the association between CYP2C19 polymorphisms and drug exposure. Due to the small number of included studies (four or fewer) in most meta-analyses, only EM/PM versus EM/EM and PM/PM versus EM/EM were included in the meta-regressions (Electronic Supplementary Material  Fig. 2 ). According to the meta-regression analysis, the influence of CYP2C19 polymorphisms did not differ between studies using AUC and those using C ss . None of the other potential confounders investigated, including drug administered (citalopram vs. escitalopram), population (healthy subjects vs. patients), gender, ethnicity (Caucasian vs. Asian), and CYP2C19*17 (available vs. non-available), demonstrated a significant modulating effect on the association between CYP2C19 genotype and (es)citalopram exposure.
Discussion
Summary of Main Results
The overall influences of individual CYP2C19 genotypes/ phenotypes on (es)citalopram exposure are presented in Fig. 3 (CYP2C19*1/*1). The precise estimate was derived from pooled data of four studies with 36 subjects homozygous for CYP2C19*17 and 237 homozygous for CYP2C19*1, and was assessed to be reliable based on the funnel plot asymmetry inspection. However, it is to be noted that there was a considerable heterogeneity among studies, indicating that the different results in individual studies may partly reflect differences in study populations and study designs. Taken together, our data from the meta-analysis demonstrates that homozygous carries of CYP2C19*17 on average achieved 36 % lower exposure to (es)citalopram, and may need higher doses to reach an exposure similar to that in subjects homozygous for CYP2C19*1.
(Es)citalopram exposure was reduced by 14 % in the UM/EM (CYP2C19*17/*1) group as compared with EM/ EM (CYP2C19*1/*1). The present study is the first ever to show this significant (p \ 0.05) though modest effect of the UM/EM genotype on (es)citalopram exposure. Subjects with the UM/PM genotype had in average 25 % higher (p \ 0.05) exposure than EM/EM. This significant effect of the UM/PM genotype on (es)citalopram exposure is also the first to be reported. Furthermore, (es)citalopram exposure was 30 % higher in EM/PM relative to EM/EM, an increase similar to that in UM/PM. This similarity may not come as a surprise, since the PM alleles (CYP2C19*2 and*3) cause complete lack of enzyme activity, while the UM allele (CYP2C19*17) does not result in twice the activity as compared with the CYP2C19*1 allele.
In the PM/PM group, the exposure was increased by 95 % compared with EM/EM, based on data from seven studies. However, the results from one study [10] differed markedly from those of the remaining studies. The strong effect of the PM/PM genotype observed in this retrospective study based on therapeutic drug monitoring samples could represent publication bias, but could also largely be due to an overrepresentation of samples collected from problematic patient cases with, for example, adverse drug reactions.
The meta-analysis demonstrated a significant effect of PMpheno on (es)citalopram exposure compared with the EMpheno group (p \ 0.0001). The average increase of 85 % in the PMpheno group was similar to that seen in the PM/PM genotype group (95 %). This similarity is reassuring, since the effect of the PM status should not be influenced by the classification method used (phenotyping or genotyping) [27] .
Overall, we demonstrated an association between CYP2C19 genotypes (UM/UM, UM/EM, EM/EM, UM/ PM, EM/PM, PM/PM) and (es)citalopram exposure, and provide precise estimates of the genotype effects. To our knowledge, this is the first meta-analysis based on a systematic review of accumulated information that addresses the association between individual CYP2C19 variants and the exposure to citalopram or escitalopram.
Limitations
This systematic meta-analysis has several limitations. Firstly, we pooled data from studies using racemic citalopram and escitalopram (S-citalopram). Since the S/R-ratio of citalopram is reported to be higher in PMs of mephenytoin compared with EMs [19] , the CYP2C19 activity could theoretically have a larger impact on the clearance of escitalopram than that of the racemic drug. We assessed citalopram and escitalopram as a covariate in the sensitivity Fig. 2 ). To further elucidate the potential differences between the two drugs, we repeated the meta-analyses after dividing the studies into those using racemic citalopram and those using escitalopram. This reanalysis (Electronic Supplementary Material Fig. 3 [28] , as exemplified by concomitant use of omeprazole (a proton pump inhibitor) being likely to cause higher plasma concentrations of citalopram. However, in the present study, we could not account for the use of potential interacting drugs or the role of other CYP enzymes (such as CYP2D6) involved in citalopram or escitalopram metabolism. Co-medications was an exclusion criterion in the studies performed in healthy subjects, but was sometimes allowed in the patient studies. The drugs used concomitantly in patient studies were rarely specified clearly. Therefore, the possible impact of drug interactions cannot be excluded as a source of inter-individual variability. Thirdly, we had to rely on aggregated group data rather than individual outcome measures, which made it difficult to detect individual-level confounding covariates. Finally, this systematic analysis is limited to published studies, and could have been influenced by publication bias. With the exception of the comparison between PM/ PM and EM/EM, we found no indication of such a bias, but the small number of studies means that selective publishing of positive studies cannot be ruled out. 
